Inventor · disambiguated record
Sabine Imhof-Jung
Also filed as: IMHOF-JUNG SABINE
28 granted patents·46 pending applications·337 citations·filing 2009–2025
96Inventor score
Top patents by PatentIndex Score
74 records- 0197US11673945B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2020·Granted Jun 13, 2023·4 cites·9 claims
- 0297US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0395US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0495US8703132B2Bispecific, tetravalent antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Apr 22, 2014·64 cites·11 claims
- 0594US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 0694US8945552B2Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2011·Granted Feb 3, 2015·36 cites·12 claims
- 0794US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 0893US11285207B2Bispecific antibodies specifically binding to PD1 and LAG3HOFFMANN LA ROCHE·Filed 2018·Granted Mar 29, 2022·10 cites·32 claims
- 0992US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 1092US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 1192US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 1292US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 1391US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 1491US10501521B2Disulfide-linked multivalent MHC class I comprising multi-function proteinsHOFFMANN LA ROCHE·Filed 2013·Granted Dec 10, 2019·39 cites·9 claims
- 1591US9388222B2Modified Pseudomonas exotoxin AUS HEALTH·Filed 2014·Granted Jul 12, 2016·15 cites·42 claims
- 1690US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 1788US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 1887US10434184B2Anti-TPBG antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Oct 8, 2019·3 cites·22 claims
- 1987US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2085US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2184US10640555B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted May 5, 2020·2 cites·2 claims
- 2284US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2383US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2482US11780919B2Bispecific antigen binding molecules targeting OX40 and FAPHOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·1 cites·24 claims
- 2582US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2682US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2781US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 2881US9676845B2Bispecific antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Jun 13, 2017·5 cites·8 claims
- 2979US2024101657A1Antibody that binds to vegf and il-1beta and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3078US2024166771A1Contorsbody - a single chain target binderHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3175US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 3273US12227594B2Bispecific 2+1 contorsbodiesHOFFMANN LA ROCHE·Filed 2018·Granted Feb 18, 2025·1 cites·14 claims
- 3373US11866490B2Antibody that binds to VEGF and IL-1beta and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Jan 9, 2024·0 cites·36 claims
- 3473US2024117049A1Bispecific antigen binding molecules targeting ox40 and fapHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3572US2021047394A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3671US11130804B2Antibody that binds to VEGF and IL-1beta and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Sep 28, 2021·0 cites·28 claims
- 3770US2023227584A1Bispecific antibodies comprising a modified c-terminal crossfab fragmentHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3869US2021347916A1Contorsbody - a single chain target binderHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 3968US2025051429A1Anti-a-beta protein antibodies, methods and uses thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4068US2023068801A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4168US2022049020A1Tetravalent multispecific antibodiesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4267US11732036B2Antibody that binds to VEGF-A and ANG2 and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Aug 22, 2023·0 cites·9 claims
- 4367US2022363771A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4467US2021024648A1Modified pseudomonas exotoxin aTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2020·Application pending·0 cites
- 4566US2022387586A1Bispecific antibodies specifically binding to pd1 and lag3HOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4665US2020181280A1Modified pseudomonas exotoxin aTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICE·Filed 2019·Application pending·0 cites
- 4765US2020216554A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4862US2021309730A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4961US2017369566A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 5061US2019389971A1The contorsbody - a single chain target binderHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Sabine Imhof-Jung files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →